(Q38001974)

26 August 2017

title

Implementing the new oral anticoagulants into the hospital formulary (English)

1 reference

26 August 2017

1 reference

Michael Palladino

1

1 reference

26 August 2017

Lynda Thomson

series ordinal

2

1 reference

26 August 2017

Brian Swift

series ordinal

3

1 reference

26 August 2017

Geno J Merli

series ordinal

4

1 reference

26 August 2017

publication date

12 April 2012

1 reference

American Journal of Hematology

26 August 2017

published in

1 reference

26 August 2017

volume

87 Suppl 1

1 reference

26 August 2017

page(s)

S127-32

1 reference

Apixaban metabolism and pharmacokinetics after oral administration to humans

26 August 2017

cites work

1 reference

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects

21 January 2018

1 reference

Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor

21 January 2018

1 reference

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

21 January 2018

1 reference

Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans

21 January 2018

1 reference

Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.

21 January 2018

1 reference

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects

21 January 2018

1 reference

Dabigatran versus warfarin in patients with atrial fibrillation

21 January 2018

1 reference

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

21 January 2018

1 reference

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty

21 January 2018

1 reference

Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial

21 January 2018

1 reference

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty

21 January 2018

1 reference

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial

21 January 2018

1 reference

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

21 January 2018

1 reference

Assays for Measuring Rivaroxaban: Their Suitability and Limitations

21 January 2018

1 reference

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23208

1 reference

26 August 2017

1 reference